New shot could help kids with tough leukemia
NCT ID NCT07134088
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a subcutaneous (under the skin) injection of blinatumomab in children under 12 with relapsed/refractory or minimal residual disease positive B-cell acute lymphoblastic leukemia. The goal is to see if this easier-to-give form is safe and effective at achieving remission. About 104 children will participate across two phases.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
blinatumomab (a drug that helps the immune system attack cancer cells)
What this could lead to
If successful, this could offer a more convenient, less invasive treatment option for children with hard-to-treat B-cell acute lymphoblastic leukemia, potentially improving remission rates.
What could go wrong
This is an early-phase trial (1b/2) with a small number of participants, so results may not apply broadly. Side effects from blinatumomab can be serious, including neurological problems and cytokine release syndrome.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Childrens Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
Kanagawa Childrens Medical Center
Yokohami-shi, Kanagawa, 232-8555, Japan
-
Lucile Packard Childrens Hospital Stanford
Palo Alto, California, 94304, United States
-
Seattle Childrens Hospital
Seattle, Washington, 98105, United States
-
St Jude Childrens Research Hospital
Memphis, Tennessee, 38105, United States